文献速递胸部肿瘤

奥希替尼联合贝伐珠单抗对比奥希替尼治疗携带EGFR突变未经治疗非鳞状非小细胞肺癌的随机2期研究:WJOG9717L研究

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
PubMed 文献 · J Thorac Oncol · 2022-05-27

这项在日本21家机构开展的随机开放标签2期研究纳入122例未经治疗的晚期非鳞状NSCLC且携带EGFR敏感突变患者,随机接受奥希替尼联合贝伐珠单抗或奥希替尼单药治疗。中位随访19.8个月,联合组中位PFS为22.1个月,单药组为20.2个月,HR为0.862(95%CI 0.531-1.397,单侧分层log-rank P=0.213),研究未能显示联合治疗改善PFS。

要点

  • 联合组中位PFS 22.1个月 vs 单药组20.2个月,HR 0.862(95%CI 0.531-1.397),未达统计学显著。
  • 3级及以上不良事件发生率联合组56%(34例) vs 单药组48%(29例)。
  • 任何级别肺炎联合组3%(2例) vs 单药组18%(11例),3级肺炎两组各2%(各1例)。

核心结论

  • 本研究未能显示奥希替尼联合贝伐珠单抗作为EGFR突变非鳞状NSCLC一线治疗改善PFS的疗效。

研究设计与样本

  • 随机、开放标签、2期研究,在日本21家机构开展。
  • 纳入122例未经治疗的晚期非鳞状NSCLC且携带EGFR敏感突变患者,按性别、分期和EGFR突变状态分层。
  • 奥希替尼联合贝伐珠单抗组61例,奥希替尼单药组61例;奥希替尼80 mg每日一次,贝伐珠单抗15 mg/kg每3周一次。
  • 主要终点为意向治疗人群的PFS,采用盲法独立中心影像学评估。

主要发现

  • 2018年1月至2018年9月入组,中位随访19.8个月。
  • 联合组中位PFS 22.1个月 vs 单药组20.2个月,HR 0.862(60%CI 0.700-1.060,95%CI 0.531-1.397,单侧分层log-rank P=0.213)。
  • 3级及以上不良事件:联合组34例(56%) vs 单药组29例(48%)。
  • 任何级别肺炎:联合组2例(3%) vs 单药组11例(18%);3级肺炎两组各1例(2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate the efficacy and safety of osimertinib plus bevacizumab for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing mutations. METHODS: We conducted a randomized, open-label, phase 2 study at 21 institutions in Japan. Previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing mutations received either osimertinib (80 mg, daily) plus bevacizumab (15 mg/kg, every 3 wk) or osimertinib monotherapy, and were stratified according to sex, stage, and EGFR mutation status. The primary end point was progression-free survival (PFS) in the intention-to-treat population, assessed by means of blinded, independent central radiologic review. RESULTS: Between January 2018 and September 2018, a total of 122 patients were enrolled (osimertinib + bevacizumab arm, 61 patients; osimertinib monotherapy arm, 61 patients). At a median follow-up duration of 19.8 months, the median PFS was 22.1 months for osimertinib plus bevacizumab and 20.2 months for osimertinib monotherapy, with a hazard ratio of 0.862 (60% confidence interval: 0.700-1.060, 95% confidence interval: 0.531-1.397, one-sided stratified log-rank p = 0.213). Adverse events of grade 3 or worse were observed in 34 patients (56%) in the osimertinib plus bevacizumab arm and 29 (48%) in the osimertinib monotherapy arm. In addition, two (3%) and 11 patients (18%) experienced any grade pneumonitis, respectively, and grade 3 pneumonitis was observed in one patient (2%) in each arm. CONCLUSIONS: This study failed to exhibit the efficacy of osimertinib plus bevacizumab for improving the PFS among patients with nonsquamous NSCLC harboring EGFR mutations as first-line treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kenmotsu H, Wakuda K, Mori K, et al. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. J Thorac Oncol. 2022. PMID: 35636696. doi:10.1016/j.jtho.2022.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。